Announcement • Jul 03
Sohm, Inc. Appoints Ravi Kapoor as an Independent Director SOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation. Announcement • Jun 13
SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human Donor SOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers. Announcement • May 24
Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024 SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development. 
